再発または難治性ホジキンリンパ腫患者の治療におけるイピリムマブ併用または非併用のブレンツキシマブ ベドチンおよびニボルマブ
再発/難治性ホジキンリンパ腫患者におけるイピリムマブ、ニボルマブ、ブレンツキシマブ ベドチンの併用に関する拡大コホート/無作為化第 II 相試験を伴う第 I 相試験
This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well they work in treating patients with Hodgkin lymphoma that has returned after a period of improvement (recurrent) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. It is not known whether giving brentuximab vedotin and nivolumab with or without ipilimumab may kill more cancer cells.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the complete response (CR) rate for the regimens of brentuximab vedotin and nivolumab compared to brentuximab vedotin, ipilimumab, and nivolumab. (Phase II; adult cohort [aged >= 18 years]) III. To characterize the safety and toxicity of treatment combination in the pediatric population. (Phase II; pediatric cohort [aged 12-17 years])
SECONDARY OBJECTIVES:
I. To evaluate complete response (CR) rate, partial response (PR) rate and overall response rate (ORR), for the combinations of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) II. To evaluate the duration of remission (DOR) to these combinations and compare with the DOR achieved with the most recent prior systemic therapy. (Phase I) III. To evaluate the progression-free survival (PFS) and the overall survival (OS) in patients receiving the combination of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase I) IV. To evaluate the ORR, PR, and stable disease (SD) rate for the combinations of brentuximab vedotin and nivolumab and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II) V. To evaluate the DOR to these combinations and compare with the DOR achieved with the most recent prior systemic therapy. (Phase II) VI. To evaluate the 5 year PFS and OS in patients receiving the combinations of brentuximab vedotin and nivolumab and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II) VII. To further evaluate the safety and characterize the toxicity for the combinations of brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab. (Phase II)
CORRELATIVE STUDY OBJECTIVES:
I. To evaluate the ability of these combinations to alter tumor specific T cell immunity. (Phase I) II. To evaluate the effects of these combinations on systemic immunity. (Phase I) III. To evaluate a panel of cytokine and T cell specific biomarkers from the peripheral blood as a potential immune signature of treatment response to therapy with these combinations for patients with relapsed/refractory Hodgkin lymphoma (HL). (Phase I) IV. To evaluate using gene expression profiling (GEP) a signature of response to these novel combinations of an antibody drug conjugate with immunomodulatory therapy. (Phase I) V. To evaluate the ability of these combinations to alter tumor specific T cell immunity, and circulating T cell phenotypes, in patients as a function of treatment response at multiple timepoints during therapy. (Phase II) VI. To evaluate peripheral blood cytokine profiles in responding and resistant patients at multiple timepoints during therapy. (Phase II) VII. To evaluate using GEP a signature of response versus (vs.) resistance to these novel combinations of an antibody drug conjugate with immunomodulatory therapy. (Phase II) VIII. To evaluate the influence of human gut microbiome dysbiosis on HL lymphomagenesis and the systemic immune response. (Phase II)
IMAGING CORRELATIVE STUDY OBJECTIVES:
I. To evaluate atypical response patterns with currently available response evaluation criteria. (Phase II) II. To correlate response evaluated using currently available response evaluation criteria with duration of response (PFS, event free survival [EFS], failure free survival [FFS]). (Phase II) III. To evaluate response patterns in different immunotherapy treatment schemes and correlate with historical data using chemotherapy. (Phase II) IV. To correlate imaging changes in all treatment schemes quantitatively with PFS. (Phase II)
EXPLORATORY OBJECTIVES:
I. Evaluate outcomes (CR, PFS) between patients with/without prior transplants. (Phase II) II. Evaluate outcomes (PFS, OS) between the patients who stay on treatment and do not go to transplant in both arms (the post auto and the few others who don't want transplant) vs the patients who go off for transplant. (Phase II) III. Evaluate outcomes (CR, PFS) in pediatric population (age 12 to < 18 years of age) vs. adult population. (Phase II)
OUTLINE: This is a phase I, dose-escalation study of brentuximab vedotin, ipilimumab, and nivolumab followed by a phase II study.
PHASE I: Patients are assigned into 1 of 3 arms.
ARM I: Patients receive brentuximab vedotin intravenously (IV) over 90 minutes on day 1 of cycles 1-16 and ipilimumab IV over 30 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity.
ARM III: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity.
PHASE II: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive brentuximab vedotin IV over 30 minutes on day 1 of cycles 1-16 and nivolumab IV over 90 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity.
All patients also undergo computed tomography (CT) or positron emission tomography (PET) scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study.
After completion of phase I study treatment, patients are followed up every 3 months for 1 year, then every 6 months for 2 years. After completion of phase II study treatment, patients are followed up for 10 years.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- University of Alabama at Birmingham Cancer Center
-
Birmingham、Alabama、アメリカ、35233
- Children's Hospital of Alabama
-
-
Alaska
-
Anchorage、Alaska、アメリカ、98508
- Anchorage Associates in Radiation Medicine
-
Anchorage、Alaska、アメリカ、99508
- Alaska Breast Care and Surgery LLC
-
Anchorage、Alaska、アメリカ、99508
- Alaska Oncology and Hematology LLC
-
Anchorage、Alaska、アメリカ、99508
- Alaska Women's Cancer Care
-
Anchorage、Alaska、アメリカ、99508
- Anchorage Oncology Centre
-
Anchorage、Alaska、アメリカ、99508
- Katmai Oncology Group
-
Anchorage、Alaska、アメリカ、99508
- Providence Alaska Medical Center
-
Anchorage、Alaska、アメリカ、99504
- Anchorage Radiation Therapy Center
-
Fairbanks、Alaska、アメリカ、99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Kingman、Arizona、アメリカ、86401
- Kingman Regional Medical Center
-
Phoenix、Arizona、アメリカ、85004
- Cancer Center at Saint Joseph's
-
-
Arkansas
-
Fort Smith、Arkansas、アメリカ、72903
- Mercy Hospital Fort Smith
-
Hot Springs、Arkansas、アメリカ、71913
- CHI Saint Vincent Cancer Center Hot Springs
-
-
California
-
Antioch、California、アメリカ、94531
- Kaiser Permanente-Deer Valley Medical Center
-
Arroyo Grande、California、アメリカ、93420
- PCR Oncology
-
Arroyo Grande、California、アメリカ、93420
- Mission Hope Medical Oncology - Arroyo Grande
-
Burbank、California、アメリカ、91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Dublin、California、アメリカ、94568
- Kaiser Permanente Dublin
-
Fremont、California、アメリカ、94538
- Kaiser Permanente-Fremont
-
Fresno、California、アメリカ、93720
- Kaiser Permanente-Fresno
-
Fresno、California、アメリカ、93720
- Fresno Cancer Center
-
Modesto、California、アメリカ、95356
- Kaiser Permanente-Modesto
-
Oakland、California、アメリカ、94611
- Kaiser Permanente-Oakland
-
Oakland、California、アメリカ、94611
- Kaiser Permanente Oakland-Broadway
-
Orange、California、アメリカ、92868
- Children's Hospital of Orange County
-
Palo Alto、California、アメリカ、94304
- Stanford Cancer Institute Palo Alto
-
Rancho Cordova、California、アメリカ、95670
- Kaiser Permanente-Rancho Cordova Cancer Center
-
Redwood City、California、アメリカ、94063
- Kaiser Permanente-Redwood City
-
Richmond、California、アメリカ、94801
- Kaiser Permanente-Richmond
-
Rohnert Park、California、アメリカ、94928
- Rohnert Park Cancer Center
-
Roseville、California、アメリカ、95678
- The Permanente Medical Group-Roseville Radiation Oncology
-
Roseville、California、アメリカ、95661
- Kaiser Permanente-Roseville
-
Sacramento、California、アメリカ、95814
- Kaiser Permanente Downtown Commons
-
Sacramento、California、アメリカ、95823
- Kaiser Permanente-South Sacramento
-
Sacramento、California、アメリカ、95823
- South Sacramento Cancer Center
-
Sacramento、California、アメリカ、95825
- Kaiser Permanente Sacramento Medical Center
-
San Francisco、California、アメリカ、94115
- Kaiser Permanente-San Francisco
-
San Francisco、California、アメリカ、94158
- UCSF Medical Center-Mission Bay
-
San Jose、California、アメリカ、95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro、California、アメリカ、94577
- Kaiser Permanente San Leandro
-
San Luis Obispo、California、アメリカ、93401
- Pacific Central Coast Health Center-San Luis Obispo
-
San Rafael、California、アメリカ、94903
- Kaiser San Rafael-Gallinas
-
San Rafael、California、アメリカ、94903
- Kaiser Permanente-San Rafael
-
Santa Clara、California、アメリカ、95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Maria、California、アメリカ、93444
- Mission Hope Medical Oncology - Santa Maria
-
Santa Rosa、California、アメリカ、95403
- Kaiser Permanente-Santa Rosa
-
South San Francisco、California、アメリカ、94080
- Kaiser Permanente Cancer Treatment Center
-
South San Francisco、California、アメリカ、94080
- Kaiser Permanente-South San Francisco
-
Stockton、California、アメリカ、95210
- Kaiser Permanente-Stockton
-
Vacaville、California、アメリカ、95688
- Kaiser Permanente Medical Center-Vacaville
-
Vallejo、California、アメリカ、94589
- Kaiser Permanente-Vallejo
-
Walnut Creek、California、アメリカ、94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora、Colorado、アメリカ、80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora、Colorado、アメリカ、80012
- The Medical Center of Aurora
-
Boulder、Colorado、アメリカ、80303
- Boulder Community Foothills Hospital
-
Boulder、Colorado、アメリカ、80304
- Rocky Mountain Cancer Centers-Boulder
-
Centennial、Colorado、アメリカ、80112
- Rocky Mountain Cancer Centers - Centennial
-
Colorado Springs、Colorado、アメリカ、80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs、Colorado、アメリカ、80907
- Rocky Mountain Cancer Centers-Penrose
-
Denver、Colorado、アメリカ、80218
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver、Colorado、アメリカ、80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
Denver、Colorado、アメリカ、80220
- Rose Medical Center
-
Denver、Colorado、アメリカ、80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver、Colorado、アメリカ、80220
- Rocky Mountain Cancer Centers-Rose
-
Denver、Colorado、アメリカ、80204
- Denver Health Medical Center
-
Denver、Colorado、アメリカ、80218
- Colorado Blood Cancer Institute
-
Denver、Colorado、アメリカ、80204
- Cancer Center of Colorado at Sloan's Lake
-
Denver、Colorado、アメリカ、80209
- The Women's Imaging Center
-
Denver、Colorado、アメリカ、80206
- National Jewish Health-Main Campus
-
Denver、Colorado、アメリカ、80220
- Western Surgical Care
-
Denver、Colorado、アメリカ、80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver、Colorado、アメリカ、80210
- AdventHealth Porter
-
Durango、Colorado、アメリカ、81301
- Mercy Medical Center
-
Durango、Colorado、アメリカ、81301
- CommonSpirit Cancer Center Mercy
-
Englewood、Colorado、アメリカ、80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood、Colorado、アメリカ、80113
- Swedish Medical Center
-
Englewood、Colorado、アメリカ、80113
- Rocky Mountain Cancer Centers - Swedish
-
Golden、Colorado、アメリカ、80401
- Mountain Blue Cancer Care Center
-
Golden、Colorado、アメリカ、80401
- National Jewish Health-Western Hematology Oncology
-
Grand Junction、Colorado、アメリカ、81501
- Saint Mary's Hospital and Regional Medical Center
-
Greeley、Colorado、アメリカ、80631
- Banner North Colorado Medical Center
-
Lafayette、Colorado、アメリカ、80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
Lakewood、Colorado、アメリカ、80228
- Rocky Mountain Cancer Centers-Lakewood
-
Lakewood、Colorado、アメリカ、80228
- CommonSpirit Saint Anthony Hospital Cancer Center
-
Littleton、Colorado、アメリカ、80120
- Rocky Mountain Cancer Centers-Littleton
-
Littleton、Colorado、アメリカ、80122
- AdventHealth Littleton
-
Lone Tree、Colorado、アメリカ、80124
- Sky Ridge Medical Center
-
Lone Tree、Colorado、アメリカ、80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Longmont、Colorado、アメリカ、80501
- Longmont United Hospital
-
Longmont、Colorado、アメリカ、80501
- Rocky Mountain Cancer Centers-Longmont
-
Loveland、Colorado、アメリカ、80539
- Banner North Colorado Medical Center - Loveland Campus
-
Parker、Colorado、アメリカ、80138
- Rocky Mountain Cancer Centers-Parker
-
Parker、Colorado、アメリカ、80138
- AdventHealth Parker
-
Pueblo、Colorado、アメリカ、81008
- Rocky Mountain Cancer Centers - Pueblo
-
Thornton、Colorado、アメリカ、80260
- Rocky Mountain Cancer Centers-Thornton
-
Thornton、Colorado、アメリカ、80260
- National Jewish Health-Northern Hematology Oncology
-
Wheat Ridge、Colorado、アメリカ、80401
- Intermountain Health Lutheran Hospital
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- Children's National Medical Center
-
-
Florida
-
Fort Myers、Florida、アメリカ、33905
- Regional Cancer Center-Lee Memorial Health System
-
Fort Myers、Florida、アメリカ、33908
- Golisano Children's Hospital of Southwest Florida
-
St. Petersburg、Florida、アメリカ、33701
- Johns Hopkins All Children's Hospital
-
Tampa、Florida、アメリカ、33606
- Tampa General Hospital
-
Tampa、Florida、アメリカ、33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta、Georgia、アメリカ、30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96819
- Kaiser Permanente Moanalua Medical Center
-
-
Idaho
-
Boise、Idaho、アメリカ、83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise、Idaho、アメリカ、83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell、Idaho、アメリカ、83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene、Idaho、アメリカ、83814
- Kootenai Health - Coeur d'Alene
-
Emmett、Idaho、アメリカ、83617
- Walter Knox Memorial Hospital
-
Fruitland、Idaho、アメリカ、83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian、Idaho、アメリカ、83642
- Idaho Urologic Institute-Meridian
-
Meridian、Idaho、アメリカ、83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa、Idaho、アメリカ、83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa、Idaho、アメリカ、83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls、Idaho、アメリカ、83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint、Idaho、アメリカ、83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls、Idaho、アメリカ、83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Alton、Illinois、アメリカ、62002
- OSF Saint Anthony's Health Center
-
Aurora、Illinois、アメリカ、60504
- Rush-Copley Medical Center
-
Bloomington、Illinois、アメリカ、61704
- Illinois CancerCare-Bloomington
-
Canton、Illinois、アメリカ、61520
- Illinois CancerCare-Canton
-
Carbondale、Illinois、アメリカ、62902
- Memorial Hospital of Carbondale
-
Carterville、Illinois、アメリカ、62918
- SIH Cancer Institute
-
Carthage、Illinois、アメリカ、62321
- Illinois CancerCare-Carthage
-
Centralia、Illinois、アメリカ、62801
- Centralia Oncology Clinic
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
Chicago、Illinois、アメリカ、60612
- University of Illinois
-
Chicago、Illinois、アメリカ、60612
- Rush MD Anderson Cancer Center
-
Danville、Illinois、アメリカ、61832
- Carle at The Riverfront
-
Decatur、Illinois、アメリカ、62526
- Decatur Memorial Hospital
-
Decatur、Illinois、アメリカ、62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon、Illinois、アメリカ、61021
- Illinois CancerCare-Dixon
-
Effingham、Illinois、アメリカ、62401
- Crossroads Cancer Center
-
Effingham、Illinois、アメリカ、62401
- Carle Physician Group-Effingham
-
Eureka、Illinois、アメリカ、61530
- Illinois CancerCare-Eureka
-
Galesburg、Illinois、アメリカ、61401
- Western Illinois Cancer Treatment Center
-
Galesburg、Illinois、アメリカ、61401
- Illinois CancerCare-Galesburg
-
Joliet、Illinois、アメリカ、60435
- Duly Health and Care Joliet
-
Kewanee、Illinois、アメリカ、61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb、Illinois、アメリカ、61455
- Illinois CancerCare-Macomb
-
Mattoon、Illinois、アメリカ、61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon、Illinois、アメリカ、62864
- SSM Health Good Samaritan
-
O'Fallon、Illinois、アメリカ、62269
- Cancer Care Center of O'Fallon
-
Ottawa、Illinois、アメリカ、61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin、Illinois、アメリカ、61554
- Illinois CancerCare-Pekin
-
Peoria、Illinois、アメリカ、61636
- Methodist Medical Center of Illinois
-
Peoria、Illinois、アメリカ、61615
- Illinois CancerCare-Peoria
-
Peru、Illinois、アメリカ、61354
- Illinois CancerCare-Peru
-
Peru、Illinois、アメリカ、61354
- Valley Radiation Oncology
-
Princeton、Illinois、アメリカ、61356
- Illinois CancerCare-Princeton
-
Springfield、Illinois、アメリカ、62702
- Southern Illinois University School of Medicine
-
Springfield、Illinois、アメリカ、62702
- Springfield Clinic
-
Springfield、Illinois、アメリカ、62781
- Springfield Memorial Hospital
-
Swansea、Illinois、アメリカ、62226
- Southwest Illinois Health Services LLP
-
Urbana、Illinois、アメリカ、61801
- Carle Cancer Center
-
Urbana、Illinois、アメリカ、61801
- The Carle Foundation Hospital
-
Washington、Illinois、アメリカ、61571
- Illinois CancerCare - Washington
-
Yorkville、Illinois、アメリカ、60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Evansville、Indiana、アメリカ、47713
- Deaconess Clinic Downtown
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Newburgh、Indiana、アメリカ、47630
- Chancellor Center for Oncology
-
-
Iowa
-
Clive、Iowa、アメリカ、50325
- Mercy Cancer Center-West Lakes
-
Clive、Iowa、アメリカ、50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs、Iowa、アメリカ、51503
- Alegent Health Mercy Hospital
-
Creston、Iowa、アメリカ、50801
- Greater Regional Medical Center
-
Des Moines、Iowa、アメリカ、50314
- Mercy Medical Center - Des Moines
-
Des Moines、Iowa、アメリカ、50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
West Des Moines、Iowa、アメリカ、50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Garden City、Kansas、アメリカ、67846
- Central Care Cancer Center - Garden City
-
Great Bend、Kansas、アメリカ、67530
- Central Care Cancer Center - Great Bend
-
-
Kentucky
-
Bardstown、Kentucky、アメリカ、40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Corbin、Kentucky、アメリカ、40701
- Commonwealth Cancer Center-Corbin
-
Lexington、Kentucky、アメリカ、40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington、Kentucky、アメリカ、40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
London、Kentucky、アメリカ、40741
- CommonSpirit Saint Joseph Hospital London
-
Louisville、Kentucky、アメリカ、40202
- Jewish Hospital
-
Louisville、Kentucky、アメリカ、40245
- UofL Health Medical Center Northeast
-
Louisville、Kentucky、アメリカ、40215
- Saints Mary and Elizabeth Hospital
-
Paducah、Kentucky、アメリカ、42003
- Mercy Health - Paducah Cancer Center
-
Shepherdsville、Kentucky、アメリカ、40165
- Jewish Hospital Medical Center South
-
-
Louisiana
-
Baton Rouge、Louisiana、アメリカ、70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge、Louisiana、アメリカ、70809
- Louisiana Hematology Oncology Associates LLC
-
Baton Rouge、Louisiana、アメリカ、70809
- Mary Bird Perkins Cancer Center
-
Baton Rouge、Louisiana、アメリカ、70808
- Our Lady of The Lake
-
Baton Rouge、Louisiana、アメリカ、70808
- Our Lady of the Lake Physician Group
-
Covington、Louisiana、アメリカ、70433
- Northshore Oncology Associates-Covington
-
Houma、Louisiana、アメリカ、70360
- Terrebonne General Medical Center
-
Houma、Louisiana、アメリカ、70360
- Oncology Center of The South Incorporated
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore、Maryland、アメリカ、21229
- Saint Agnes Hospital
-
Bethesda、Maryland、アメリカ、20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02111
- Tufts Medical Center
-
-
Michigan
-
Port Huron、Michigan、アメリカ、48060
- Lake Huron Medical Center
-
Port Huron、Michigan、アメリカ、48060
- Huron Medical Center PC
-
-
Minnesota
-
Aitkin、Minnesota、アメリカ、56431
- Riverwood Healthcare Center
-
Brainerd、Minnesota、アメリカ、56401
- Essentia Health Saint Joseph's Medical Center
-
Deer River、Minnesota、アメリカ、56636
- Essentia Health - Deer River Clinic
-
Detroit Lakes、Minnesota、アメリカ、56501
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth、Minnesota、アメリカ、55805
- Essentia Health Cancer Center
-
Duluth、Minnesota、アメリカ、55805
- Essentia Health Saint Mary's Medical Center
-
Duluth、Minnesota、アメリカ、55805
- Miller-Dwan Hospital
-
Fergus Falls、Minnesota、アメリカ、56537
- Lake Region Healthcare Corporation-Cancer Care
-
Fosston、Minnesota、アメリカ、56542
- Essentia Health - Fosston
-
Hibbing、Minnesota、アメリカ、55746
- Essentia Health Hibbing Clinic
-
Park Rapids、Minnesota、アメリカ、56470
- Essentia Health - Park Rapids
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic in Rochester
-
Sandstone、Minnesota、アメリカ、55072
- Essentia Health Sandstone
-
Virginia、Minnesota、アメリカ、55792
- Essentia Health Virginia Clinic
-
-
Missouri
-
Ballwin、Missouri、アメリカ、63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar、Missouri、アメリカ、65613
- Central Care Cancer Center - Bolivar
-
Bonne Terre、Missouri、アメリカ、63628
- Parkland Health Center-Bonne Terre
-
Branson、Missouri、アメリカ、65616
- Cox Cancer Center Branson
-
Cape Girardeau、Missouri、アメリカ、63703
- Saint Francis Medical Center
-
Cape Girardeau、Missouri、アメリカ、63703
- Mercy Cancer Center - Cape Girardeau
-
Chesterfield、Missouri、アメリカ、63017
- Saint Luke's Hospital
-
City of Saint Peters、Missouri、アメリカ、63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur、Missouri、アメリカ、63141
- Siteman Cancer Center at West County Hospital
-
Farmington、Missouri、アメリカ、63640
- Parkland Health Center - Farmington
-
Jefferson City、Missouri、アメリカ、65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin、Missouri、アメリカ、64804
- Freeman Health System
-
Joplin、Missouri、アメリカ、64804
- Mercy Hospital Joplin
-
Kansas City、Missouri、アメリカ、64108
- Children's Mercy Hospitals and Clinics
-
Rolla、Missouri、アメリカ、65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla、Missouri、アメリカ、65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph、Missouri、アメリカ、64506
- Heartland Regional Medical Center
-
Sainte Genevieve、Missouri、アメリカ、63670
- Sainte Genevieve County Memorial Hospital
-
Springfield、Missouri、アメリカ、65807
- CoxHealth South Hospital
-
Springfield、Missouri、アメリカ、65804
- Mercy Hospital Springfield
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63129
- Siteman Cancer Center-South County
-
St Louis、Missouri、アメリカ、63136
- Siteman Cancer Center at Christian Hospital
-
St Louis、Missouri、アメリカ、63131
- Missouri Baptist Medical Center
-
St Louis、Missouri、アメリカ、63109
- Mercy Infusion Center - Chippewa
-
St Louis、Missouri、アメリカ、63141
- Mercy Hospital Saint Louis
-
St Louis、Missouri、アメリカ、63128
- Mercy Hospital South
-
Sullivan、Missouri、アメリカ、63080
- Missouri Baptist Sullivan Hospital
-
Washington、Missouri、アメリカ、63090
- Mercy Hospital Washington
-
-
Montana
-
Anaconda、Montana、アメリカ、59711
- Community Hospital of Anaconda
-
Billings、Montana、アメリカ、59101
- Billings Clinic Cancer Center
-
Billings、Montana、アメリカ、59101
- Saint Vincent Healthcare
-
Billings、Montana、アメリカ、59102
- Saint Vincent Frontier Cancer Center
-
Bozeman、Montana、アメリカ、59715
- Bozeman Health Deaconess Hospital
-
Butte、Montana、アメリカ、59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls、Montana、アメリカ、59405
- Great Falls Clinic
-
Great Falls、Montana、アメリカ、59405
- Benefis Sletten Cancer Institute
-
Helena、Montana、アメリカ、59601
- Saint Peter's Community Hospital
-
Kalispell、Montana、アメリカ、59901
- Logan Health Medical Center
-
Missoula、Montana、アメリカ、59802
- Saint Patrick Hospital - Community Hospital
-
Missoula、Montana、アメリカ、59804
- Community Medical Center
-
-
Nebraska
-
Grand Island、Nebraska、アメリカ、68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney、Nebraska、アメリカ、68847
- CHI Health Good Samaritan
-
Kearney、Nebraska、アメリカ、68845
- Fred and Pamela Buffett Cancer Center - Kearney
-
Lincoln、Nebraska、アメリカ、68510
- Saint Elizabeth Regional Medical Center
-
Omaha、Nebraska、アメリカ、68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha、Nebraska、アメリカ、68122
- Alegent Health Immanuel Medical Center
-
Omaha、Nebraska、アメリカ、68130
- Alegent Health Lakeside Hospital
-
Omaha、Nebraska、アメリカ、68122
- Hematology and Oncology Consultants PC
-
Papillion、Nebraska、アメリカ、68046
- Midlands Community Hospital
-
-
Nevada
-
Carson City、Nevada、アメリカ、89703
- Carson Tahoe Regional Medical Center
-
Henderson、Nevada、アメリカ、89052
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson、Nevada、アメリカ、89052
- Cancer and Blood Specialists-Henderson
-
Henderson、Nevada、アメリカ、89052
- Las Vegas Cancer Center-Henderson
-
Henderson、Nevada、アメリカ、89074
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Henderson、Nevada、アメリカ、89052
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson、Nevada、アメリカ、89074
- Las Vegas Urology - Green Valley
-
Henderson、Nevada、アメリカ、89074
- Las Vegas Urology - Pebble
-
Henderson、Nevada、アメリカ、89074
- Urology Specialists of Nevada - Green Valley
-
Henderson、Nevada、アメリカ、89074
- Oncology Las Vegas - Henderson
-
Las Vegas、Nevada、アメリカ、89144
- Summerlin Hospital Medical Center
-
Las Vegas、Nevada、アメリカ、89109
- Sunrise Hospital and Medical Center
-
Las Vegas、Nevada、アメリカ、89102
- OptumCare Cancer Care at Charleston
-
Las Vegas、Nevada、アメリカ、89106
- Radiation Oncology Centers of Nevada Central
-
Las Vegas、Nevada、アメリカ、89119
- Radiation Oncology Centers of Nevada Southeast
-
Las Vegas、Nevada、アメリカ、89128
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas、Nevada、アメリカ、89128
- OptumCare Cancer Care at MountainView
-
Las Vegas、Nevada、アメリカ、89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas、Nevada、アメリカ、89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas、Nevada、アメリカ、89144
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas、Nevada、アメリカ、89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas、Nevada、アメリカ、89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas、Nevada、アメリカ、89102
- University Medical Center of Southern Nevada
-
Las Vegas、Nevada、アメリカ、89106
- Cancer and Blood Specialists-Shadow
-
Las Vegas、Nevada、アメリカ、89109
- HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
-
Las Vegas、Nevada、アメリカ、89113
- HealthCare Partners Medical Group Oncology/Hematology-San Martin
-
Las Vegas、Nevada、アメリカ、89128
- Cancer and Blood Specialists-Tenaya
-
Las Vegas、Nevada、アメリカ、89128
- HealthCare Partners Medical Group Oncology/Hematology-Tenaya
-
Las Vegas、Nevada、アメリカ、89148-2405
- Las Vegas Cancer Center-Medical Center
-
Las Vegas、Nevada、アメリカ、89149
- HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
-
Las Vegas、Nevada、アメリカ、89128
- Ann M Wierman MD LTD
-
Las Vegas、Nevada、アメリカ、89074
- Las Vegas Urology - Pecos
-
Las Vegas、Nevada、アメリカ、89102
- Desert West Surgery
-
Las Vegas、Nevada、アメリカ、89103
- Hope Cancer Care of Nevada
-
Las Vegas、Nevada、アメリカ、89106
- Urology Specialists of Nevada - Central
-
Las Vegas、Nevada、アメリカ、89113
- Las Vegas Prostate Cancer Center
-
Las Vegas、Nevada、アメリカ、89113
- Las Vegas Urology - Sunset
-
Las Vegas、Nevada、アメリカ、89128
- Las Vegas Urology - Cathedral Rock
-
Las Vegas、Nevada、アメリカ、89128
- Las Vegas Urology - Smoke Ranch
-
Las Vegas、Nevada、アメリカ、89128
- Urology Specialists of Nevada - Northwest
-
Las Vegas、Nevada、アメリカ、89169
- University Cancer Center
-
Las Vegas、Nevada、アメリカ、89113
- Urology Specialists of Nevada - Southwest
-
Las Vegas、Nevada、アメリカ、89128
- Oncology Las Vegas - Tenaya
-
Las Vegas、Nevada、アメリカ、89183
- OptumCare Cancer Care at Fort Apache
-
Pahrump、Nevada、アメリカ、89048
- Hope Cancer Care of Nevada-Pahrump
-
Reno、Nevada、アメリカ、89502
- Renown Regional Medical Center
-
Reno、Nevada、アメリカ、89503
- Saint Mary's Regional Medical Center
-
Reno、Nevada、アメリカ、89509
- Radiation Oncology Associates
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- Hackensack University Medical Center
-
Lakewood、New Jersey、アメリカ、08701
- Monmouth Medical Center Southern Campus
-
Long Branch、New Jersey、アメリカ、07740
- Monmouth Medical Center
-
Morristown、New Jersey、アメリカ、07960
- Morristown Medical Center
-
New Brunswick、New Jersey、アメリカ、08903
- Rutgers Cancer Institute of New Jersey
-
New Brunswick、New Jersey、アメリカ、08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany、New York、アメリカ、12208
- Albany Medical Center
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center
-
New York、New York、アメリカ、10029
- Mount Sinai Hospital
-
New York、New York、アメリカ、10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York、New York、アメリカ、10065
- NYP/Weill Cornell Medical Center
-
New York、New York、アメリカ、10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Stony Brook、New York、アメリカ、11794
- Stony Brook University Medical Center
-
Syracuse、New York、アメリカ、13210
- State University of New York Upstate Medical University
-
The Bronx、New York、アメリカ、10467
- Montefiore Medical Center - Moses Campus
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte、North Carolina、アメリカ、28203
- Carolinas Medical Center/Levine Cancer Institute
-
Clinton、North Carolina、アメリカ、28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro、North Carolina、アメリカ、27534
- Southeastern Medical Oncology Center-Goldsboro
-
Goldsboro、North Carolina、アメリカ、27534
- Wayne Memorial Hospital
-
Jacksonville、North Carolina、アメリカ、28546
- Southeastern Medical Oncology Center-Jacksonville
-
Jacksonville、North Carolina、アメリカ、28546
- Onslow Memorial Hospital
-
-
North Dakota
-
Fargo、North Dakota、アメリカ、58103
- Essentia Health Cancer Center-South University Clinic
-
Jamestown、North Dakota、アメリカ、58401
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Akron、Ohio、アメリカ、44308
- Children's Hospital Medical Center of Akron
-
Cincinnati、Ohio、アメリカ、45229
- Cincinnati Children's Hospital Medical Center
-
Cincinnati、Ohio、アメリカ、45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati、Ohio、アメリカ、45242
- Bethesda North Hospital
-
Cincinnati、Ohio、アメリカ、45247
- TriHealth Cancer Institute-Westside
-
Cincinnati、Ohio、アメリカ、45255
- TriHealth Cancer Institute-Anderson
-
Cleveland、Ohio、アメリカ、44109
- MetroHealth Medical Center
-
Columbus、Ohio、アメリカ、43205
- Nationwide Children's Hospital
-
-
Oklahoma
-
Lawton、Oklahoma、アメリカ、73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City、Oklahoma、アメリカ、73120
- Mercy Hospital Oklahoma City
-
Tulsa、Oklahoma、アメリカ、74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Baker City、Oregon、アメリカ、97814
- Saint Alphonsus Cancer Care Center-Baker City
-
Bend、Oregon、アメリカ、97701
- Saint Charles Health System
-
Clackamas、Oregon、アメリカ、97015
- Clackamas Radiation Oncology Center
-
Clackamas、Oregon、アメリカ、97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay、Oregon、アメリカ、97420
- Bay Area Hospital
-
Newberg、Oregon、アメリカ、97132
- Providence Newberg Medical Center
-
Ontario、Oregon、アメリカ、97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City、Oregon、アメリカ、97045
- Providence Willamette Falls Medical Center
-
Portland、Oregon、アメリカ、97213
- Providence Portland Medical Center
-
Portland、Oregon、アメリカ、97225
- Providence Saint Vincent Medical Center
-
Redmond、Oregon、アメリカ、97756
- Saint Charles Health System-Redmond
-
-
Pennsylvania
-
Hershey、Pennsylvania、アメリカ、17033-0850
- Penn State Milton S Hershey Medical Center
-
Philadelphia、Pennsylvania、アメリカ、19111
- Fox Chase Cancer Center
-
Philadelphia、Pennsylvania、アメリカ、19104
- Children's Hospital of Philadelphia
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania/Abramson Cancer Center
-
-
South Carolina
-
Boiling Springs、South Carolina、アメリカ、29316
- Prisma Health Cancer Institute - Spartanburg
-
Columbia、South Carolina、アメリカ、29203
- Prisma Health Richland Hospital
-
Easley、South Carolina、アメリカ、29640
- Prisma Health Cancer Institute - Easley
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Cancer Institute - Faris
-
Greenville、South Carolina、アメリカ、29607
- Saint Francis Cancer Center
-
Greenville、South Carolina、アメリカ、29615
- Prisma Health Cancer Institute - Eastside
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Cancer Institute - Butternut
-
Greenville、South Carolina、アメリカ、29601
- Saint Francis Hospital
-
Greenville、South Carolina、アメリカ、29605
- BI-LO Charities Children's Cancer Center
-
Greenville、South Carolina、アメリカ、29605
- Prisma Health Greenville Memorial Hospital
-
Greer、South Carolina、アメリカ、29650
- Prisma Health Cancer Institute - Greer
-
Seneca、South Carolina、アメリカ、29672
- Prisma Health Cancer Institute - Seneca
-
-
Tennessee
-
Chattanooga、Tennessee、アメリカ、37404
- Memorial Hospital
-
Hixson、Tennessee、アメリカ、37343
- Pulmonary Medicine Center of Chattanooga-Hixson
-
Knoxville、Tennessee、アメリカ、37916
- East Tennessee Childrens Hospital
-
Memphis、Tennessee、アメリカ、38105
- Saint Jude Children's Research Hospital
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville、Tennessee、アメリカ、37203
- The Children's Hospital at TriStar Centennial
-
Ooltewah、Tennessee、アメリカ、37363
- Memorial GYN Plus
-
-
Texas
-
Austin、Texas、アメリカ、78723
- Dell Children's Medical Center of Central Texas
-
Bryan、Texas、アメリカ、77802
- Saint Joseph Regional Cancer Center
-
Corpus Christi、Texas、アメリカ、78411
- Driscoll Children's Hospital
-
El Paso、Texas、アメリカ、79905
- El Paso Children's Hospital
-
Fort Worth、Texas、アメリカ、76104
- Cook Children's Medical Center
-
San Antonio、Texas、アメリカ、78207
- Children's Hospital of San Antonio
-
-
Utah
-
American Fork、Utah、アメリカ、84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City、Utah、アメリカ、84720
- Sandra L Maxwell Cancer Center
-
Logan、Utah、アメリカ、84321
- Logan Regional Hospital
-
Murray、Utah、アメリカ、84107
- Intermountain Medical Center
-
Ogden、Utah、アメリカ、84403
- McKay-Dee Hospital Center
-
Riverton、Utah、アメリカ、84065
- Riverton Hospital
-
Salt Lake City、Utah、アメリカ、84106
- Utah Cancer Specialists-Salt Lake City
-
Salt Lake City、Utah、アメリカ、84143
- LDS Hospital
-
St. George、Utah、アメリカ、84770
- Saint George Regional Medical Center
-
-
Virginia
-
Norfolk、Virginia、アメリカ、23507
- Children's Hospital of The King's Daughters
-
-
Washington
-
Aberdeen、Washington、アメリカ、98520
- Providence Regional Cancer System-Aberdeen
-
Auburn、Washington、アメリカ、98001
- MultiCare Auburn Medical Center
-
Bellevue、Washington、アメリカ、98004
- Overlake Medical Center
-
Bellingham、Washington、アメリカ、98225
- PeaceHealth Saint Joseph Medical Center
-
Burien、Washington、アメリカ、98166
- Saint Anne Hospital
-
Centralia、Washington、アメリカ、98531
- Providence Regional Cancer System-Centralia
-
Edmonds、Washington、アメリカ、98026
- Swedish Cancer Institute-Edmonds
-
Enumclaw、Washington、アメリカ、98022
- Saint Elizabeth Hospital
-
Everett、Washington、アメリカ、98201
- Providence Regional Cancer Partnership
-
Federal Way、Washington、アメリカ、98003
- Saint Francis Hospital
-
Gig Harbor、Washington、アメリカ、98335
- MultiCare Gig Harbor Medical Park
-
Issaquah、Washington、アメリカ、98029
- Swedish Cancer Institute-Issaquah
-
Kennewick、Washington、アメリカ、99336
- Kadlec Clinic Hematology and Oncology
-
Lacey、Washington、アメリカ、98503
- Providence Regional Cancer System-Lacey
-
Lakewood、Washington、アメリカ、98499
- Saint Clare Hospital
-
Longview、Washington、アメリカ、98632
- PeaceHealth Saint John Medical Center
-
Port Townsend、Washington、アメリカ、98368
- Jefferson Healthcare
-
Poulsbo、Washington、アメリカ、98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Puyallup、Washington、アメリカ、98372
- MultiCare Good Samaritan Hospital
-
Renton、Washington、アメリカ、98055
- Valley Medical Center
-
Seattle、Washington、アメリカ、98105
- Seattle Children's Hospital
-
Seattle、Washington、アメリカ、98107
- Swedish Medical Center-Ballard Campus
-
Seattle、Washington、アメリカ、98122
- Swedish Medical Center-First Hill
-
Seattle、Washington、アメリカ、98112
- Kaiser Permanente Washington
-
Seattle、Washington、アメリカ、98104
- Pacific Gynecology Specialists
-
Seattle、Washington、アメリカ、98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley、Washington、アメリカ、98284
- PeaceHealth United General Medical Center
-
Shelton、Washington、アメリカ、98584
- Providence Regional Cancer System-Shelton
-
Silverdale、Washington、アメリカ、98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane、Washington、アメリカ、99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Spokane、Washington、アメリカ、99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane、Washington、アメリカ、99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
Spokane Valley、Washington、アメリカ、99216
- MultiCare Deaconess Cancer and Blood Specialty Center - Valley
-
Tacoma、Washington、アメリカ、98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma、Washington、アメリカ、98405
- Northwest Medical Specialties PLLC
-
Tacoma、Washington、アメリカ、98431
- Madigan Army Medical Center
-
Tacoma、Washington、アメリカ、98405
- MultiCare Tacoma General Hospital
-
Tacoma、Washington、アメリカ、98405
- Franciscan Research Center-Northwest Medical Plaza
-
Vancouver、Washington、アメリカ、98664
- PeaceHealth Southwest Medical Center
-
Walla Walla、Washington、アメリカ、99362
- Providence Saint Mary Regional Cancer Center
-
Yakima、Washington、アメリカ、98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
Yelm、Washington、アメリカ、98597
- Providence Regional Cancer System-Yelm
-
-
West Virginia
-
Bridgeport、West Virginia、アメリカ、26330
- United Hospital Center
-
Martinsburg、West Virginia、アメリカ、25401
- WVUH-Berkely Medical Center
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University Healthcare
-
Parkersburg、West Virginia、アメリカ、26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Ashland、Wisconsin、アメリカ、54806
- Duluth Clinic Ashland
-
Ashland、Wisconsin、アメリカ、54806
- Northwest Wisconsin Cancer Center
-
Burlington、Wisconsin、アメリカ、53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Chippewa Falls、Wisconsin、アメリカ、54729
- Marshfield Clinic-Chippewa Center
-
Eau Claire、Wisconsin、アメリカ、54701
- Marshfield Medical Center-EC Cancer Center
-
Fond du Lac、Wisconsin、アメリカ、54937
- Aurora Health Center-Fond du Lac
-
Germantown、Wisconsin、アメリカ、53022
- Aurora Health Care Germantown Health Center
-
Grafton、Wisconsin、アメリカ、53024
- Aurora Cancer Care-Grafton
-
Green Bay、Wisconsin、アメリカ、54311
- Aurora BayCare Medical Center
-
Kenosha、Wisconsin、アメリカ、53142
- Aurora Cancer Care-Kenosha South
-
La Crosse、Wisconsin、アメリカ、54601
- Gundersen Lutheran Medical Center
-
Ladysmith、Wisconsin、アメリカ、54848
- Marshfield Medical Center - Ladysmith
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette、Wisconsin、アメリカ、54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield、Wisconsin、アメリカ、54449
- Marshfield Medical Center-Marshfield
-
Milwaukee、Wisconsin、アメリカ、53226
- Medical College of Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee、Wisconsin、アメリカ、53215
- Aurora Saint Luke's Medical Center
-
Milwaukee、Wisconsin、アメリカ、53233
- Aurora Sinai Medical Center
-
Minocqua、Wisconsin、アメリカ、54548
- Marshfield Medical Center - Minocqua
-
Oshkosh、Wisconsin、アメリカ、54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine、Wisconsin、アメリカ、53406
- Aurora Cancer Care-Racine
-
Rice Lake、Wisconsin、アメリカ、54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan、Wisconsin、アメリカ、53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point、Wisconsin、アメリカ、54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit、Wisconsin、アメリカ、53066
- Aurora Medical Center in Summit
-
Two Rivers、Wisconsin、アメリカ、54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wausau、Wisconsin、アメリカ、54401
- Marshfield Clinic-Wausau Center
-
Wauwatosa、Wisconsin、アメリカ、53226
- Aurora Cancer Care-Milwaukee West
-
West Allis、Wisconsin、アメリカ、53227
- Aurora West Allis Medical Center
-
Weston、Wisconsin、アメリカ、54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids、Wisconsin、アメリカ、54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Wyoming
-
Cheyenne、Wyoming、アメリカ、82001
- Cheyenne Regional Medical Center-West
-
Cody、Wyoming、アメリカ、82414
- Billings Clinic-Cody
-
Sheridan、Wyoming、アメリカ、82801
- Welch Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
PHASE I (ARMS A, B, C, D, E, F, G, H, I, X, Y, Z)
-
Age >= 18 years
-
Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including lymphocyte predominant (LP) HL are not permitted
-
Patients must have relapsed after first line chemotherapy; may have relapsed after autologous or allogeneic stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; if status post allogeneic stem cell transplant, no active graft versus host disease
-
Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within 6 months prior to registration, and must not have relapsed within 6 months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD1/PDL1 axis agents; patients in the nivolumab/brentuximab cohorts ONLY (D, E, F, Y) may have received prior ipilimumab
-
Patients may have received other prior activating immunotherapies (i.e. checkpoint inhibitors), but must not have received them within 6 months prior to registration, and there must be no serious unresolved complication of therapy at the time of registration; for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)
-
Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) performance status between 0-2
-
Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan; patients must use the same imaging modality (CT or PET/CT) throughout the study
-
Patient must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all patients of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a patient of childbearing potential is anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patient of childbearing potential and/or sexually active patients must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both single barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for patients of childbearing potential) and for 7 months after the last dose of study drug (for patients who are sexually active with anyone of childbearing potential); should a patient become pregnant or suspect pregnancy while the patient or their partner is participating in this study, the patient (or the participating partner) should inform the treating physician immediately
-
Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while breathing room air
-
Patients must have forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registration
-
Absolute neutrophil count (ANC) >= 1500/mcL (1.5 x 10^9/L) (obtained within 2 weeks prior to registration)
-
Platelets >= 75,000/mcL (75 x 10^9/L) (obtained within 2 weeks prior to registration)
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) (obtained within 2 weeks prior to registration)
-
Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert's syndrome, for which bilirubin =< 3 x upper limit of normal [ULN] is permitted) (obtained within 2 weeks prior to registration)
-
Calculated creatinine clearance by Cockcroft-Gault formula >= 30 ml/min (obtained within 2 weeks prior to registration)
-
No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic response
-
Patient must have no current or prior history of central nervous system (CNS) involvement
-
All prior therapy must have been completed at least 21 days prior to enrollment; no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed
-
No history of Steven's Johnson's syndrome, toxic epidermal necrolysis (TEN)s syndrome, or motor neuropathy
-
Human immunodeficiency virus (HIV) positive patients are allowed on this study if they have a CD4 count > 400, and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded
-
Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed
- Replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to initiation of study treatment are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study
- Exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other CNS autoimmune disease (e.g., Multiple sclerosis); patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible
-
Patients must not have grade 2 or greater peripheral sensory neuropathy
-
Patients must not have New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia
-
Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab
-
Patients must not have a serious medical or psychiatric illness likely to interfere with study participation
-
Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration
-
Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment
-
Patients registering to Arms D, E, F, G, H, I, X, Y must not currently be smoking tobacco or other substances and must not have smoked within the past 6 months
-
RANDOMIZED PHASE II (ARMS K AND L): Age >= 12 years
- Pediatric patients will include any patients < 18 years of age
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must have pathologically confirmed relapsed or refractory classical Hodgkin lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including lymphocyte predominant (LP) HL are not permitted
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must have relapsed after first line chemotherapy; may have relapsed after autologous stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; patient must not have received a prior allogeneic stem cell transplant (out of risk of reactivation of pulmonary graft versus host disease [GVHD])
-
RANDOMIZED PHASE II (ARMS K AND L): Patients may have received prior brentuximab vedotin, but must not have received brentuximab vedotin within 6 months prior to registration, and must not have relapsed within 6 months of receiving previous brentuximab vedotin; patients may not have received prior nivolumab or PD1/PDL1 axis agents; patients may not have received prior ipilimumab
-
RANDOMIZED PHASE II (ARMS K AND L): Patients may not have received other prior activating immunotherapies (i.e. checkpoint inhibitor therapies); for the purposes of this study monoclonal antibodies and antibody drug conjugates are not considered to be activating immunotherapies and there are no additional time restrictions on prior exposure to these agents (except prior brentuximab vedotin)
-
RANDOMIZED PHASE II (ARMS K AND L): Adult patient (>= 18 years of age) ECOG-ACRIN performance status between 0-2
- Pediatric patients (16-17 years of age) must have a Karnofsky performance level >= 50%
- Pediatric patients (12-15 years of age) must have a Lansky performance level >= 50
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must have measurable disease; baseline measurements and evaluations must be obtained within 4 weeks of registration to the study; abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan; patients must use the same imaging modality (CT or PET/CT) throughout the study
-
RANDOMIZED PHASE II (ARMS K AND L): Patient must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol; all patients of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
RANDOMIZED PHASE II (ARMS K AND L): Patient of childbearing potential and/or sexually active patient must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both double barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug (for patients of childbearing potential) and for 7 months after the last dose of study drug (for patients who are sexually active with anyone of childbearing potential); should a patient become pregnant or suspect pregnancy while the patient or their partner is participating in this study, the patient (or the participating partner) should inform the treating physician immediately
-
RANDOMIZED PHASE II (ARMS K AND L): Patients with impaired decision-making capacity are eligible with legally authorized representative
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must have no evidence of dyspnea at rest and a pulse oximetry > 92% while breathing room air
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must have FEV1/FVC > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registration
-
RANDOMIZED PHASE II (ARMS K AND L): ANC >= 1500/mcL (1.5 x 0^9/L) (obtained within 2 weeks prior to registration)
-
RANDOMIZED PHASE II (ARMS K AND L): Platelets >= 75,000/mcL (75 x 10^9/L) (obtained within 2 weeks prior to registration)
-
RANDOMIZED PHASE II (ARMS K AND L): AST/ALT =< 2.5 x upper limit of normal (ULN) for age (obtained within 2 weeks prior to registration)
-
RANDOMIZED PHASE II (ARMS K AND L): Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert's syndrome, for which bilirubin =< 3 x upper limit of normal [ULN] is permitted) (obtained within 2 weeks prior to registration)
-
RANDOMIZED PHASE II (ARMS K AND L): Adult patients (>= 18 years old) must have a calculated creatinine clearance by Cockcroft-Gault formula >= 30 ml/min (obtained within 2 weeks prior to registration)
-
RANDOMIZED PHASE II (ARMS K AND L): Pediatric patients (< 18 years old) must have a creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or serum creatinine based on age/sex as follows:
-
Age: maximum serum creatinine (mg/dL)
- < 13 years: male (1.2), female (1.2)
- 13 to < 16 years: male (1.5), female (1.4)
- >= 16 years: male (1.7), female (1.4)
-
-
RANDOMIZED PHASE II (ARMS K AND L): No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma or any surgically- or radiation-cured malignancy continuously disease free for >= 5 years so as not to interfere with interpretation of radiographic response
-
RANDOMIZED PHASE II (ARMS K AND L): Patient must have no current or prior history of CNS involvement
-
RANDOMIZED PHASE II (ARMS K AND L): All prior therapy must have been completed at least 21 days prior to enrollment (6 weeks for nitrosoureas or mitomycin C); no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed
-
RANDOMIZED PHASE II (ARMS K AND L): No history of Steven's Johnson's syndrome, TENs syndrome, or motor neuropathy
-
RANDOMIZED PHASE II (ARMS K AND L): HIV positive patients are eligible provided they meet the other protocol criteria including the following:
- Long term survival expected were it not for the cHL
- HIV viral loads undetectable by standard clinical HIV testing
- Willing to adhere to effective combination antiretroviral therapy
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have autoimmune disorders, prior solid organ transplant, or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of steroid medication for at least 2 weeks prior to initiation of therapy are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study; exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other CNS autoimmune disease (e.g., Multiple sclerosis); patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have grade 2 or greater peripheral sensory neuropathy
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have NYHA class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have previously existing hypersensitivity to brentuximab vedotin or ipilimumab
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have a serious medical or psychiatric illness likely to interfere with study participation
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration
-
RANDOMIZED PHASE II (ARMS K AND L): Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatment
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not currently be smoking tobacco or other agents; vaping is not allowed
-
RANDOMIZED PHASE II (ARMS K AND L): Patients must not have a history of or evidence of cardiovascular risks including any of the following:
- QT interval corrected for heart rate using the Bazett's formula QTcB >= 480 msec at baseline
- History of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within the past 24 weeks prior to registration
- History prior to registration or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system
- Left ventricular ejection fraction (LVEF) =< lower limit of normal on cardiac echocardiogram (echo) or multigated acquisition scan (MUGA)
- Intra-cardiac defibrillator
- History of abnormal cardiac valve morphology (>= grade 2) documented by ECHO; (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study); subjects with moderate valvular thickening should not be entered on study
- History or evidence of current clinically significant uncontrolled cardiac arrhythmias; clarification: subjects with atrial fibrillation controlled for > 30 days prior to dosing are eligible
- Treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mm Hg which cannot be controlled by anti-hypertensive therapy
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Phase I Arm I (brentuximab vedotin, ipilimumab)
Patients receive brentuximab vedotin IV over 30 minutes on day 1 of cycles 1-16 and ipilimumab IV over 90 minutes on day 1 of cycles 1-4, 8, 12, and 16. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study. |
Given IV
他の名前:
Undergo CT
他の名前:
Undergo biopsy
他の名前:
Undergo collection of blood
他の名前:
Given IV
他の名前:
Undergo PET
他の名前:
|
|
実験的:Phase I Arm II (brentuximab vedotin, nivolumab)
Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-46. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study. |
Undergo CT
他の名前:
Undergo biopsy
他の名前:
Undergo collection of blood
他の名前:
Given IV
他の名前:
Undergo PET
他の名前:
Given IV
他の名前:
|
|
実験的:Phase I Arm III (brentuximab vedotin, nivolumab, ipilimumab)
Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-46, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 16 cycles and every 14 days beginning cycle 17 for up to 46 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study. |
Given IV
他の名前:
Undergo CT
他の名前:
Undergo biopsy
他の名前:
Undergo collection of blood
他の名前:
Given IV
他の名前:
Undergo PET
他の名前:
Given IV
他の名前:
|
|
実験的:Phase II Arm I (brentuximab vedotin, nivolumab)
Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16 and nivolumab IV over 30 minutes on day 1 of cycles 1-34. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study. |
Undergo CT
他の名前:
Undergo biopsy
他の名前:
Undergo collection of blood
他の名前:
Given IV
他の名前:
Undergo PET
他の名前:
Given IV
他の名前:
|
|
実験的:Phase II Arm II (brentuximab vedotin, nivolumab, ipilimumab)
Patients receive brentuximab vedotin IV over 90 minutes on day 1 of cycles 1-16, nivolumab IV over 30 minutes on day 1 of cycles 1-34, and ipilimumab IV over 30 minutes on day 1 every 12 weeks for up to 9 doses. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or PET scan throughout the trial. Patients undergo blood sample collection and may undergo tumor biopsy on study. |
Given IV
他の名前:
Undergo CT
他の名前:
Undergo biopsy
他の名前:
Undergo collection of blood
他の名前:
Given IV
他の名前:
Undergo PET
他の名前:
Given IV
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum tolerated dose (MTD) of each combination (Phase I)
時間枠:21 days
|
MTD defined as the highest dose level at which less than 33% of 6 patients experience a dose limiting toxicity, will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Upon completion of the trial, frequency of subjects experiencing toxicities will be tabulated. Toxicities will be assessed and graded according to CTCAE version 4.0 terminology. Exact 95% confidence intervals (CI) around the toxicity proportions will be calculated. |
21 days
|
|
CR rate (Phase II)
時間枠:Up to 10 years
|
The analysis of CR between two arms will be performed using exact Cochran-Mantel-Haenszel (CMH) test stratifying on prior brentuximab vedotin (BV) (yes versus [vs.] no) and age (< 18 vs. >= 18). Multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes. |
Up to 10 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Complete response (CR) rate (Phase I)
時間枠:Up to 3 years
|
Assessed using the Revised Response Criteria for Malignant Lymphoma and reported along with the 95% CI. |
Up to 3 years
|
|
Partial response (PR) rate (Phase I)
時間枠:Up to 3 years
|
Assessed using the Revised Response Criteria for Malignant Lymphoma and reported along with the 95% CI. |
Up to 3 years
|
|
Overall response rate (ORR) rate (Phase I)
時間枠:Up to 3 years
|
Assessed using the Revised Response Criteria for Malignant Lymphoma and reported along with the 95% CI. |
Up to 3 years
|
|
Duration of response (DOR) (Phase I)
時間枠:From the documented beginning of response up to 3 years
|
DOR will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% CI for the Kaplan-Meier estimates. Descriptive statistics will be used to evaluate the DOR achieved with the protocol therapy and with the most recent prior systemic therapy. |
From the documented beginning of response up to 3 years
|
|
Overall survival (OS) (Phase I)
時間枠:From the date of study entry up to 3 years
|
OS will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% CI for the Kaplan-Meier estimates. |
From the date of study entry up to 3 years
|
|
Progression-free survival (PFS) (Phase I)
時間枠:From entry onto study up to 3 years
|
PFS will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% CI for the Kaplan-Meier estimates. |
From entry onto study up to 3 years
|
|
ORR (Phase II)
時間枠:Up to 10 years
|
Assessed using Revised Response (Cheson) and Deauville criteria. The analysis of ORR between two arms will be performed using the CMH test stratifying on prior BV (yes vs. no) and age (< 18 vs. >= 18). Multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes. |
Up to 10 years
|
|
PFS (or modified PFS) (Phase II)
時間枠:From randomization up to 10 years
|
PFS will be estimated using Kaplan-Meier methodology and compared between arms using stratified log-rank test. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Cox proportional regression model will be used to estimate hazard ratios (95% CI) and assess the relationship between other prognostic factors with time-to-event outcome. Point estimates of all endpoints will be accompanied by the corresponding 95% confidence intervals. |
From randomization up to 10 years
|
|
OS (Phase II)
時間枠:From randomization up to 10 years
|
OS will be estimated using Kaplan-Meier methodology and compared between arms using stratified log-rank test. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Cox proportional regression model will be used to estimate hazard ratios (95% CI) and assess the relationship between other prognostic factors with time-to-event outcome. Point estimates of all endpoints will be accompanied by the corresponding 95% confidence intervals. |
From randomization up to 10 years
|
|
DOR (Phase II)
時間枠:From the documented beginning of response up to 10 years
|
DOR, will be estimated using Kaplan-Meier methodology and compared between arms using stratified log-rank test. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Cox proportional regression model will be used to estimate hazard ratios (95% CI) and assess the relationship between other prognostic factors with time-to-event outcome. Point estimates of all endpoints will be accompanied by the corresponding 90% confidence intervals. The DOR achieved with the most recent prior systemic therapy will be collected on the case report forms, and descriptive statistics will be used to evaluate the DOR achieved with the protocol therapy and with the most recent prior systemic therapy. |
From the documented beginning of response up to 10 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
全身性免疫に対する組み合わせの効果 (フェーズ I および II)
時間枠:研究治療の完了後6週間までのベースライン
|
研究治療の完了後6週間までのベースライン
|
|
|
Change in the percentage of activated T cells and natural killer cells (Phase I and II)
時間枠:Baseline (Time 1) to 9 weeks (Time 3, time of first re-staging)
|
These quantities of interest will be calculated for each patient and the Wilcoxon signed-rank test will be used to test for significant difference between the time points. Using Wilcoxon rank sum test (two-sided type I error of 0.1), differences between those who progress or die within one year versus (vs.) those who are event-free at one year will be evaluated. |
Baseline (Time 1) to 9 weeks (Time 3, time of first re-staging)
|
|
Change in the percentages of activated T cells and natural killer cells (Phase I and II)
時間枠:Day 1 of cycle 2 (Time 2) or 9 weeks (Time 3) to up to 6 weeks after completion of study treatment (Time 4, end of study)
|
These quantities of interest will be calculated for each patient and the Wilcoxon signed-rank test will be used to test for significant difference between the time points. Using the Wilcoxon rank sum test (two-sided type I error of 0.1), differences between those who progress or die within one year vs. those who are event-free at one year will be evaluated. |
Day 1 of cycle 2 (Time 2) or 9 weeks (Time 3) to up to 6 weeks after completion of study treatment (Time 4, end of study)
|
|
Pre- and post-treatment levels of cytokines and T cell specific biomarkers (Phase I and II)
時間枠:Baseline to up to 6 weeks after completion of study treatment
|
Pre- and post-treatment levels of these markers will be compared using the Wilcoxon signed-rank test with two-sided type I error of 0.1. Marker levels between patients who fail at 1-year vs. patients who are event-free at 1-year will be evaluated. Given limited data, the analyses of PD-1, co-expression of Tim-3 with PD-1, ICOS, sCD30, galectin-1 and the peripheral blood absolute lymphocyte to monocyte ratio will be mainly exploratory and will be summarized descriptively at the time-points described above. The association with PFS will be explored. |
Baseline to up to 6 weeks after completion of study treatment
|
|
Differentially expressed genes between two groups (patients who fail at 1-year vs. patients who are event-free at 1-year or responders vs. non-responders) (Phase I and II)
時間枠:1 year
|
Assessed using gene expression profiling (GEP). Differentially expressed genes will be identified using a rank-based method developed by Dr. Hong (RankProd, R package, Bioconductor Project) with multiple comparison adjustment using a false discovery rate approach. A two-way unsupervised hierarchical clustering analysis will be applied to both the genes and the samples to illustrate whether GEP can separate two groups or is associated with other clinical factors. The genes ranked as most significant will be assessed by gene ontology and pathway analysis for their potential functions in lymphoma biology and treatment failure. |
1 year
|
|
Microbiome analysis (Phase I and II)
時間枠:Completion of study treatment
|
Will compare the gut microbiome between Hodgkin lymphoma (HL) patients and healthy controls with respect to global diversity, taxonomic abundance, and bacterial functional pathways. The relative abundance of each taxon (phyla to genera) and functional pathways among different groups will be statistically compared in univariate analysis using t-test (or Wilcoxon test) and in multivariate analysis using logistic regression. Global diversity tests and multivariate analysis for taxonomic abundance and functional pathways will be adjusted for potential confounders (age, sex, race, and body mass index) in the comparisons of HL patients and controls, and further adjusted for stage and grade when examining the clinical response among HL patients. |
Completion of study treatment
|
|
Absolute maximum standard uptake value (SUVmax) (Phase II)
時間枠:Up to cycle 10
|
Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, event free survival (EFS), OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (Kaplan-Meier [KM] curve and log-rank testing). |
Up to cycle 10
|
|
Metabolic whole body tumor volume (MTV) and tumor lesion glycolysis (TLG)
時間枠:Up to cycle 10
|
Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing). |
Up to cycle 10
|
|
Percent change in SUVmax, MTV and TLG between baseline and during therapy
時間枠:Baseline up to cycle 10
|
Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing). |
Baseline up to cycle 10
|
|
Percent change in size (sum of perpendicular diameters [SPD]) on computed tomography (CT)
時間枠:Baseline up to cycle 10
|
Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing). |
Baseline up to cycle 10
|
|
Absolute CT tumor volumes
時間枠:Up to cycle 10
|
Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing). |
Up to cycle 10
|
|
Percent change in CT size (SPD) and in CT tumor volume between baseline and during therapy
時間枠:Baseline up to cycle 10
|
Image data will be evaluated using Lugano response criteria with various D 5PS cut-offs in the entire cohort and in different therapy cohorts to determine if the existing set of criteria is sufficient to segregate the group into various response categories. Will correlate PFS, EFS, OS 5PS in two reading settings (1-3 [negative] vs 4-5 [positive] and D 5PS 1-4 [negative] vs 5 [positive]) (KM curve and log-rank testing). |
Baseline up to cycle 10
|
協力者と研究者
捜査官
- 主任研究者:Catherine S Diefenbach、ECOG-ACRIN Cancer Research Group
出版物と役立つリンク
一般刊行物
- Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Sharon E, Streicher H, Kahl BS, Ansell SM. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020 Sep;7(9):e660-e670. doi: 10.1016/S2352-3026(20)30221-0.
- Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28.
- Gonzalez-Kozlova E, Huang HH, Jagede OA, Tuballes K, Del Valle DM, Kelly G, Patel M, Xie H, Harris J, Argueta K, Nie K, Barcessat V, Moravec R, Altreuter J, Duose DY, Kahl BS, Ansell SM, Yu J, Cerami E, Lindsay JR, Wistuba II, Kim-Schulze S, Diefenbach CS, Gnjatic S. Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma. Cancer Res Commun. 2024 Jul 1;4(7):1726-1737. doi: 10.1158/2767-9764.CRC-24-0252.
- Mu-Mosley H, von Itzstein MS, Fattah F, Liu J, Zhu C, Xie Y, Wakeland EK, Park JY, Kahl BS, Diefenbach CS, Gerber DE. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities. Oncoimmunology. 2024 May 9;13(1):2351255. doi: 10.1080/2162402X.2024.2351255. eCollection 2024.
- Diefenbach CS, Jegede O, Wang V, Ansell SM, Kostakoglu L, Steidl C, Natkunam Y, Scott DW, Ambinder RF, David KA, Advani RH, Bartlett NL, Robertson MJ, Thomas SP, Cohen J, Ibrahimi S, Goyal G, Mehta-Shah N, Amengual JE, Forlenza CJ, Cole PD, Duan F, Kelly K, Kahl BS. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026 Apr 30;147(18):2041-2052. doi: 10.1182/blood.2025029546.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- ペプチド
- アミノ酸、ペプチド、およびタンパク質
- オリゴペプチド
- タンパク質
- 調査手法
- 臨床検査技術
- 診断技術と手順
- 診断
- 外科的処置、手術
- 細胞学的技術
- 細胞診断
- 生物学的要因
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 診断技術、外科的
- 化学技術、分析
- スペクトル分析
- 受容体、細胞表面
- 膜タンパク質
- 抗原
- 抗原、表面
- バイオマーカー
- 受容体、免疫学的
- 抗原、分化、Tリンパ球
- 抗原、分化
- 免疫チェックポイントタンパク質
- 共刺激および阻害性T細胞受容体
- ニボルマブ
- イピリムマブ
- ブレンツキシマブ ベドチン
- 生検
- 標本処理
- 磁気共鳴分光法
- CTLA-4抗原
その他の研究ID番号
- NCI-2013-01275
- U10CA180820 (米国 NIH グラント/契約)
- U24CA196172 (米国 NIH グラント/契約)
- NCI-2013-01275 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- E4412 (その他の識別子:CTEP)
- S14-00011
- E4412
- E4412 (その他の識別子:ECOG-ACRIN Cancer Research Group)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。